345 results about "Aplastic bone marrow" patented technology

New methods are provided for suppressing the immune system and for treating immune related disorders. Therapies of the invention include administration of an FLT3 inhibitor compound to a subject in need thereof, such as a subject suffering from organ rejection, bone marrow transplant rejection, acquired immune deficiency syndrome, arthritis, aplastic anemia, graft-versus-host disease, Graves' disease, established experimental allergic encephalitomyelitis, multiple sclerosis, lupus, or a neurological disorder. Methods are also provided for screening therapeutic agents for treating immune disorders, including the use of a mouse having an elevated level of FLT3 receptor activity.

A Chinese medicine in the form of table, capsule, particle, powder, pill, etc for treating aplastic anemia, iron-deficiency anemia, and leukocytopenia is prepared from 21 Chinese-medicinal materials including donkey-hide gelatin, Chinese angelica root, astragalus root, mother wort, etc. Its advantage is high curative effect.

The invention discloses a traditional Chinese medicine for the treatment of aplastic anemia, which belongs to the technology field of traditional Chinese medicine, and the medicine for the treatment of the aplastic anemia is mainly prepared by pilose Asiabell root, membranous milkvetch root, rhizome, heterophylly falsestarwort root, fragrant solomonseal rhizome, coastal glehnia root, figwort root, barbary wolfberry fruit, dwarf lilyturf tuber, tuber fleeceflower root, largehead atractylodes rhizome, Chinese angelica, Indian buead, epimedium herb, south dodder seed, desertliving cistanche, danshen root, sanchi, glossy privet fruit, yerbadetajo herb, hairy antler, Chinese magnoliavine fruit, radix rehmanniae preparata, cassia bark, liquoric root and divaricate saposhnikovia root according to a certain weight proportion.

The invention discloses a Chinese medicine combination used for warming kidney, invigorating spleen, supplementing Qi and nourishing blood and a preparation method of the Chinese medicine combination. The effective compositions of the invention are extracted from ginseng, Atractylodes macrocephaia, dodder, milk veteh, Tuckahoe, wolfberry fruit, angelica, root of herbaceous peony, old arable soil, Ligustrum lucidum, fleece-flower root, Eclipta alba, Salvia miltiorrhiza, Caulis Spatholobi, colla corii asini, pulp of cornus and Glycyrrhiza, etc. The medicinal active compositions specific to the invention has the functions of warming kidney, invigorating spleen, supplementing Qi and nourishing blood and is applicable for spleen and kidney deficiency and vital energy and blood deficiency. For clinical treatment, the medicine combination can be used for treating aplastic anemia, on-deficiency anemia, nutritional anemia, chornic anemia, drug-induced anemia or autoimmune hemolytic anemia, thrombocytopenia and aleukocytosis and so on.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

The invention relates to a traditional Chinese medicine preparation which is an oral traditional Chinese medicine for treating aplastic anemia.The medicine preparation is made from the following raw medicines in proportion: radix astragali, dangshen, dried longan pulp, white paeony root, cortex moutan, herba ecliptae, turtle shell, hairyvein agrimonia herb and bund, polygonum, Chinese dodder seed, yam, mantis egg-case which have respectively 13 to 15g, and sojutsu var, angelica, rehmanniae vaporata, rhizoma ligustici wallichii, poria cocos, desertliving cistanche, liquoric root which respectively have 8 to 10g as well as donkey hide gelatin which has 7 to 8g and 7 to 8 red jujubes. The invention is characterized by novel prescription, low cost, convenient preparation and remarkable effect.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

Compounds of structural formula (I) are disclosed as useful for modulating the androgen receptor (AR) in a tissue selective manner in a patient in need of such modulation, and in particular for antagonizing AR in the prostate of a male patient or in the uterus of a female patient and agonizing AR in bone and/or muscle tissue. These compounds are useful in the treating conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including: osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, post-menopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, arthritis and joint repair, alone or in combination with other active agents. In addition, these compounds are useful as pharmaceutical composition ingredients alone and in combination with other active agents.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

The present invention relates to a preventive or therapeutic agent for pathological conditions caused by reduced production of erythropoietin, or for anemia, or for chronic anemia, renal anemia, aplastic anemia, or pure red cell aplasia, the agent comprising, as an active ingredient, a cyclic amine compound represented by the following formula (1):

wherein,

• • R¹, R² and R³ each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group;
  • W¹ and W² each independently represent N or CH;
  • X represents O, NR⁴, CONR⁴ or NR⁴CO;
  • R⁴ each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

The invention discloses a medicine for treating AIDS, and relates to a traditional Chinese medicine. The medicine is characterized by being made from the following raw materials: 15-25g of angelica, 25-35g of astragalus root, 25-35g of morinda root, 15-25g of red sage root and 1-15g of cassia. The following bulk drugs can also be added: spatholobus stem, pepper, largehead atractylodes, achyranthes root, black bean, pilose asiabell root, sheep manure, clematis root, dried ginger, fibrous root of fistular onion, fly larval and the like. The medicine is prepared by the following steps: taking the raw materials, soaking for 30-40m, adding 700-1000g of water, decocting with slow fire for 15-25m after boiling, and separating dregs from the decoction for oral administration; and baking and grinding the dregs into powder for oral administration. The medicine has the efficacies of invigorating spleen and stomach, invigorating vital energy and producing saliva, recuperating internal organs, nourishing blood and liver, promoting blood circulation to clear channels, enriching the blood and strengthening the bone, and killing viruses. The medicine is used for treating AIDS and has the curative ratio up to 97.7%, and can be also widely applied to treating diseases such as leukemia, aplastic anemia, thrombocytopenia, hepatitis, dermatosis and the like.

The invention provides a combined medicine containing metformin hydrochloride and vitamin B12, which can prevent and treat diabetic peripheral neuropathy to the maximal extent, prevent metformin hydrochloride from inducing hyperhomocysteinemia, malabsorption of vitamin B12 to cause megaloblastic anemia, and treat aplastic anemia and the like.

The invention discloses a medicament for treating regenerative anemia which is prepared from Chinese herbs of ginseng, cow-bezoar, pulp of dogwood fruit, polygala root, banksia rose, prepared rhizome of rehmannia, white atractylodes rhizome, licorice root, astragalus root, poria cocos, Chinese caterpillar fungus, cimicifuga rhizome, spine date seed, hairy deerhorn, longan pulp, Chinese angelica root, poria with hostwood, Cinnamomum cassia, slice of aconite, schisandra fruit, dried ginger, root of red rooted saliva and motherwort.

The invention discloses traditional Chinese medicine composition for treating aplastic anemia and a preparation method, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared to form a formula according to the principle of the monarch, the minister, the assistant andthe guide; in the formula, astragalus, dried rehmannia roots, cooked rehmannia roots, glossy privet fruits and the like serve as the monarch; barbarywolfberry fruits, herbaepimedii, moutan bark, Chinese wolfberry root-bark, deerhorn glue and the like serve as the minister; herbaecliptae, ass hide glue, red paeony roots and the like serve as the assistant; and red dates, liquorice and the like serve as the guide; all the medicines are combined to achieve effects of curing livers, spleens and kidneys simultaneously and recovering functions of hematopoietic stem cells. The composition is mainly used for treating the aplastic anemia, can increase marrow hematopoietic cells, can remove hectic fever due to yin deficiency, can repair bones and add marrow, has an obvious promoting effect on generation of granulocytic erythrocytes and erythroid progenitor cells, can accelerate generation, differentiation and maturity of the hematopoietic cells, can improve the immune function, reduce damage to immune leukocytes, stimulate and activate the hematopoietic function, enables erythrocytes to generate blood vigorously, can promote generation of the erythrocytes and the leukocytes, can increase the number of blood platelets, can enhance functions of the blood platelets and the like.

The invention provides a use of chlorogenic acid in preparing medicament for treating thrombocytopenia and anemia and also provides a pharmaceutical composition containing the chlorogenic acid as the active constituent. The chlorogenic acid can treat anemia caused by various reasons, wherein the anemia contains post-hemorrhagic anemia, hemolytic anemia, macrocytic anemia and aplastic anemia.

The invention discloses a blood plasma product for clinical transfusion and a preparation method thereof. The blood plasma product is prepared from cord blood. The preparation method is as follows: the cord blood in placeta umbilic, which is wasted from a term birth infant, is collected and is centrifuged, and nucleated cells are removed; ABO and Rh blood type detection, blood cell and blood plasma component measurement, pathogenic microorganism immunoassay and germiculture are carried out on the obtained blood plasma without the nucleated cells; and qualified blood plasma is detected, a proper amount of protective agent is added, spin-freeze is carried out at the temperature of minus 35 DEG C for 2 hours, and then freeze-drying is carried out at the temperature of 35 DEG C-37 DEG C within 18-20 hours to obtain the freeze-dried cord blood plasma product. The transfusion comprises common clinical transfusion and transfusion in the aspects of malignant tumor subject to chemo-treatment/radiation treatment and poor hematopoiesis diseases caused by aplastic anemia. The cord blood is a special transfusion resource with important treatment function and also a source of important candidate stem cells.

The invention discloses a medicine for curing the aplastic anemia, which is composed of following materials: astragalus root, radix codonopsitis, arillus longan, placenta, shelled cedar seed, redpine leaf, downy rosemyrtle fruit, ophiopogon root, hairy antler, glue of tortoise plastron, angelica, prepared rhizome of adhesive rehmannia, donkey-hide glue, chickens gizzard membrane, millet sprout, peanut coat, sanchi, dragon blood, flower of Chinese scholartree, saffron, dicliptera chinensis, lithospermum, beautyberry, honeysuckle, cassia seed, ophicalcite, lobedfruit schizocapsa rhizome and scandent schefflera stem and leaf. The medicine has obvious curative effect for curing the aplastic anemia and can rapidly improve the anaemia symptoms, and has accurate curative effect after taking the medicine; the medicine is convenient to be used and has no side effects and no recurrence after recovery; the efficiency ratio is 91%; and the recovery ratio is 75%.

The invention discloses a Chinese patent medicament for treating aplastic anemia. The Chinese patent medicament comprises the following Chinese herbal medicines: prepared rehmannia root, figwort root, dwarf lilyturf tuber, oriental waterplantain rhizome, mulberry, India madder root, gardenia, tree paeony bark, lalang grass rhizome and the like. The Chinese patent medicament contains fewer ingredients according to a formula, is mixed scientifically, does not have toxic or side effect, and has an obvious treatment effect on acute and chronic aplastic anemia. By the treatment with the Chinese patent medicament, the effective rate of the aplastic anemia is over 90 percent, and the cure rate is over 80 percent. The Chinese patent medicament has a good clinical treatment effect on aplastic anemia and has the high safety of clinical administration, and bone marrow transplantation is prevented, so the treatment cost is low.